|
1
|
Mezawa S, Homma H, Sato T, Doi T,
Miyanishi K, Takada K, Kukitsu T, Murase K, Yoshizaki N, Takahashi
M, et al: A study of carboplatin-coated tube for the unresectable
cholangiocarcinoma. Hepatology. 32:916–923. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalinowski M, Alfke H, Kleb B, Dürfeld F
and Joachim Wagner H: Paclitaxel inhibits proliferation of cell
lines responsible for metal stent obstruction: Possible topical
application in malignant bile duct obstructions. Invest Radiol.
37:399–404. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park SW, Lee DH, Park YS, Chung JB, Kang
JK and Song SY: Percutaneous transhepatic choledochoscopic
injection of ethanol with OK-432 mixture for palliation of
malignant biliary obstruction. Gastrointest Endosc. 57:769–773.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee DH, Kang SG, Jeong S, Yoon CJ, Choi
JA, Byun JN, Park JH and Lee KB: Local delivery system of immune
modulating drug for unresectable adenocarcinoma: In vitro
experimental study and in vivo animal study. Cardiovasc Intervent
Radiol. 29:832–837. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee DK, Kim HS, Kim KS, Lee WJ, Kim HK,
Won YH, Byun YR, Kim MY, Baik SK and Kwon SO: The effect on porcine
bile duct of a metallic stent covered with a
paclitaxel-incorporated membrane. Gastrointest Endosc. 61:296–301.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee SS, Shin JH, Han JM, Cho CH, Kim MH,
Lee SK, Kim JH, Kim KR, Shin KM, Won YH and Song HY: Histologic
influence of paclitaxel-eluting covered metallic stents in a canine
biliary model. Gastrointest Endosc. 69:1140–1147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suk KT, Kim JW, Kim HS, Baik SK, Oh SJ,
Lee SJ, Kim HG, Lee DH, Won YH and Lee DK: Human application of a
metallic stent covered with a paclitaxel-incorporated membrane for
malignant biliary obstruction: Multicenter pilot study.
Gastrointest Endosc. 66:798–803. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mekhail TM and Markman M: Paclitaxel in
cancer therapy. Expert Opin Pharmacother. 3:755–766. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Markman M, Rowinsky E, Hakes T, Reichman
B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M,
et al: Phase I trial of intraperitoneal taxol: A gynecoloic
oncology group study. J Clin Oncol. 10:1485–1491. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burt HM, Jackson JK, Bains SK, Liggins RT,
Oktaba AM, Arsenault AL and Hunter WL: Controlled delivery of taxol
from microspheres composed of a blend of ethylene-vinyl acetate
copolymer and poly (d,l-lactic acid). Cancer Lett. 88:73–79. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dhanikula AB and Panchagnula R: Localized
paclitaxel delivery. Int J Pharm. 183:85–100. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pawar R, Shikanov A, Vaisman B and Domb
AJ: Intravenous and regional paclitaxel formulations. Curr Med
Chem. 11:397–402. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kang SG, Lee SC, Choi SH, Park S, Jeong S,
Lee HD and Kim M: Paclitaxel-polyurethane film for anti-cancer drug
delivery: Film characterization and preliminary in vivo study.
Macromol Res. 18:680–685. 2010. View Article : Google Scholar
|
|
14
|
Uchiyama-Kokubu N and Watanabe T:
Establishment and characterization of adriamycin-resistant human
colorectal adenocarcinoma HCT-15 cell lines with multidrug
resistance. Anticancer Drugs. 12:769–779. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee SH, Yoo SD and Lee KH: Rapid and
sensitive determination of paclitaxel in mouse plasma by
high-performance liquid chromatography. J Chromatogr B Biomed Sci
Appl. 724:357–363. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mittal B, Deutsch M and Iwatsuki S:
Primary cancers of extrahepatic biliary passages. Int J Radiat
Oncol Biol Phys. 11:849–854. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Klatskin G: Adenocarcinoma of the hepatic
duct at its bifurcation within the porta hepatis. an unusual tumor
with distinctive clinical and pathological features. Am J Med.
38:241–256. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harvey JH, Smith FP and Schein PS:
5-fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of
the biliary tract. J Clin Oncol. 2:1245–1248. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Falkson G, MacIntyre JM and Moertel CG:
Eastern cooperative oncology group experience with chemotherapy for
inoperable gallbladder and bile duct cancer. Cancer. 54:965–969.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Altaee MY, Johnson PJ, Farrant JM and
Williams R: Etiologic and clinical characteristics of peripheral
and hilar cholangiocarcinoma. Cancer. 68:2051–2055. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones DV Jr, Lozano R, Hoque A, Markowitz
A and Patt YZ: Phase II study of paclitaxel therapy for
unresectable biliary tree carcinomas. J Clin Oncol. 14:2306–2310.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Buskirk SJ, Gunderson LL, Adson MA,
Martinez A, May GR, McIlrath DC, Nagorney DM, Edmundson GK, Bender
CE and Martin JK Jr: Analysis of failure following curative
irradiation of gallbladder and extrahepatic bile duct carcinoma.
Int J Radiat Oncol Biol Phys. 10:2013–2023. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Flickinger JC, Epstein AH, Iwatsuki S,
Carr BI and Starzl TE: Radiation therapy for primary carcinoma of
the extrahepatic biliary system. An analysis of 63 cases. Cancer.
68:289–294. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsujino K, Landry JC, Smith RG, Keller JW,
Williams WH and Davis LW: Definitive radiation therapy for
extrahepatic bile duct carcinoma. Radiology. 196:275–280. 1995.
View Article : Google Scholar : PubMed/NCBI
|
